Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis
This study confirms the real-world effectiveness of osimertinib in Peruvian patients with advanced EGFR T790M positive NSCLC and highlights the importance of timely detection and access to targeted therapies.
Authors
- Rossana Ruiz (ORCID: https://orcid.org/0000-0001-5199-6686)
- Luis A. Mas (ORCID: https://orcid.org/0000-0002-2323-9271)
- Ofelia Coanqui (ORCID: https://orcid.org/0000-0002-1637-8732)
- Tatiana Vidaurre (ORCID: https://orcid.org/0000-0003-1995-4560)
- George Oblitas
- Mivael Olivera (ORCID: https://orcid.org/0000-0003-4127-0800)
- Victor Paitan (ORCID: https://orcid.org/0000-0003-1120-4335)
- Jorge Zegarra
- Jesus Pino (ORCID: https://orcid.org/0000-0003-1920-9392)
- Natalia Valdiviezo (ORCID: https://orcid.org/0000-0002-4300-5958)
- Fernando Namuche
- Marco A. Galvez Nino (ORCID: https://orcid.org/0000-0002-1408-4474)
- Kátia Roque (ORCID: https://orcid.org/0000-0003-3267-7107)
- Alfredo Aguilar Cartagena
- Juan Carlos Ezquerra
- Lorenzo Maco
- Roberto Coello
- R. Roca
- Lisde González
- Maria del Pilar Cabrera
- Tulio Arrese
Institutions
- International Potato Center (PE)
- Universidad Peruana Cayetano Heredia (PE)
- Good Hope Hospital (GB)
- United States Naval Medical Research Unit SOUTH (PE)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- EsSALUD (PE)
- Forum Solidaridad Perú (PE)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100906
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00